Cadence Pharmaceuticals, (FRA:QEW) LT-Debt-to-Total-Asset : 0.20 (As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cadence Pharmaceuticals,'s long-term debt to total assests ratio for the quarter that ended in Dec. 2013 was 0.20.

Cadence Pharmaceuticals,'s long-term debt to total assets ratio declined from Dec. 2012 (0.30) to Dec. 2013 (0.20). It may suggest that Cadence Pharmaceuticals, is progressively becoming less dependent on debt to grow their business.

Cadence Pharmaceuticals, LT-Debt-to-Total-Asset Historical Data

The historical data trend for Cadence Pharmaceuticals,'s LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, LT-Debt-to-Total-Asset Chart

Cadence Pharmaceuticals, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.15

0.18

0.30

0.20

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.30	0.28	0.27	0.25	0.20

Cadence Pharmaceuticals, LT-Debt-to-Total-Asset Calculation

Cadence Pharmaceuticals,'s Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2013 is calculated as

LT Debt to Total Assets (A: Dec. 2013 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2013 )	/	Total Assets (A: Dec. 2013 )
	=	13.533	/	66.286
	=	0.20

Cadence Pharmaceuticals,'s Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2013 is calculated as

LT Debt to Total Assets (Q: Dec. 2013 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2013 )	/	Total Assets (Q: Dec. 2013 )
	=	13.533	/	66.286
	=	0.20

Cadence Pharmaceuticals, (FRA:QEW) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cadence Pharmaceuticals, LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, (FRA:QEW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines